Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Smoking, Symptoms Improvement, and Total Antioxidant Capacity in Patients with Drug-naive First-episode Schizophrenia: A Prospective Cohort Study

Author(s): Zhiyong Gao, Meihong Xiu, Jiahong Liu, Fengchun Wu* and Xiangyang Zhang*

Volume 22, Issue 10, 2024

Published on: 19 October, 2023

Page: [1733 - 1741] Pages: 9

DOI: 10.2174/1570159X22666231019105328

Price: $65

conference banner
Abstract

Background: It has been hypothesized that smoking is associated with the severity of negative symptoms. Until now, no studies have investigated whether the impact of smoking on negative symptoms is dependent on antioxidants. This study was designed to evaluate the effect of smoking on therapeutic response and total antioxidants capacity (TAOC) in antipsychotic-naïve first-episode (ANFE) patients.

Methods: The severity of the patient’s symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS). A total of 237 ANFE patients were recruited and treated with risperidone (oral tablets, 4-6 mg/day twice a day) for 12 weeks. PANSS was assessed at baseline and a 12-week follow-up. Plasma TAOC levels were also assayed at baseline and week 12.

Results: Relative to nonsmokers with ANFE SZ, smokers had higher PANSS negative subscores. There was no significant difference in TAOC changes after 12 weeks of treatment with risperidone between smokers and non-smokers. However, we found greater improvement in negative symptoms in smokers compared to non-smokers. Further analysis in smokers with SZ demonstrated that improvements in negative symptoms were not associated with changes in TAOC.

Conclusion: Our study suggested that smoking affected the severity of baseline negative symptoms and further contributed to their reduction after risperidone treatment. However, improvement in negative symptoms was not dependent on the changes in TAOC.

« Previous Next »
Graphical Abstract

[1]
Fang, X.; Chen, Y.; Wang, Y.; Ren, J.; Zhang, C. Depressive symptoms in schizophrenia patients: A possible relationship between SIRT1 and BDNF. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2019, 95, 109673.
[http://dx.doi.org/10.1016/j.pnpbp.2019.109673] [PMID: 31247244]
[2]
Fang, X.; Chen, Y.; Wang, Y.; Zhang, C. Identification of risk factors for suicidal ideation in patients with schizophrenia. Psychiatry Res., 2019, 271, 195-199.
[http://dx.doi.org/10.1016/j.psychres.2018.11.051] [PMID: 30500709]
[3]
Xiu, M.H.; Lang, X.; Chen, D.C.; Cao, B.; Kosten, T.R.; Cho, R.Y.; Shi, H.; Wei, C.W.; Wu, A.S.; Zhang, X.Y. Cognitive deficits and clinical symptoms with hippocampal subfields in first-episode and never-treated patients with Schizophrenia. Cereb. Cortex, 2021, 31(1), 89-96.
[http://dx.doi.org/10.1093/cercor/bhaa208] [PMID: 32901269]
[4]
Xiu, M.H.; Li, Z.; Chen, D.C.; Chen, S.; Curbo, M.E.; Wu, H.E.; Tong, Y.S.; Tan, S.P.; Zhang, X.Y. Interrelationships between BDNF, superoxide dismutase, and cognitive impairment in drug-naive first-episode patients with Schizophrenia. Schizophr. Bull., 2020, 46(6), 1498-1510.
[http://dx.doi.org/10.1093/schbul/sbaa062] [PMID: 32390043]
[5]
Šagud, M.; Vuksan-Ćusa, B.; Jakšić, N.; Mihaljević-Peleš, A.; Rojnić, K.M.; Pivac, N. Smoking in Schizophrenia: An updated review. Psychiatr. Danub., 2018, 30(Suppl. 4), 216-223.
[PMID: 29864763]
[6]
Ding, J.B.; Hu, K. Cigarette smoking and schizophrenia: Etiology, clinical, pharmacological, and treatment implications. Schizophr. Res. Treatment, 2021, 2021, 1-8.
[http://dx.doi.org/10.1155/2021/7698030] [PMID: 34938579]
[7]
Changeux, J.P. Nicotine addiction and nicotinic receptors: Lessons from genetically modified mice. Nat. Rev. Neurosci., 2010, 11(6), 389-401.
[http://dx.doi.org/10.1038/nrn2849] [PMID: 20485364]
[8]
Dome, P.; Lazary, J.; Kalapos, M.P.; Rihmer, Z. Smoking, nicotine and neuropsychiatric disorders. Neurosci. Biobehav. Rev., 2010, 34(3), 295-342.
[http://dx.doi.org/10.1016/j.neubiorev.2009.07.013] [PMID: 19665479]
[9]
Zhu, M.H.; Liu, Z.J.; Hu, Q.Y.; Yang, J.Y.; Jin, Y.; Zhu, N.; Huang, Y.; Shi, D.H.; Liu, M.J.; Tan, H.Y.; Zhao, L.; Lv, Q.Y.; Yi, Z.H.; Wu, F.C.; Li, Z.Z. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: A 12-week randomized, double-blind, placebo-controlled trial. Mil. Med. Res., 2022, 9(1), 59.
[http://dx.doi.org/10.1186/s40779-022-00420-0] [PMID: 36253804]
[10]
Addington, J.; el-Guebaly, N.; Campbell, W.; Hodgins, D.C.; Addington, D. Smoking cessation treatment for patients with schizophrenia. Am. J. Psychiatry, 1998, 155(7), 974-975.
[http://dx.doi.org/10.1176/ajp.155.7.974] [PMID: 9659869]
[11]
Sandyk, R. Cigarette smoking: effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia. Int. J. Neurosci., 1993, 70(3-4), 193-197.
[http://dx.doi.org/10.3109/00207459309000574] [PMID: 8063538]
[12]
Taiminen, T.J.; Salokangas, R.K.R.; Saarijärvi, S.; Niemi, H.; Lehto, H.; Ahola, V.; Syvälahti, E. Smoking and cognitive deficits in schizophrenia: A pilot study. Addict. Behav., 1998, 23(2), 263-266.
[http://dx.doi.org/10.1016/S0306-4603(97)00028-2] [PMID: 9573430]
[13]
Dépatie, L.; O’Driscoll, G.A.; Holahan, A.L.; Atkinson, V.; Thavundayil, J.X.; Kin, N.N.; Lal, S. Nicotine and behavioral markers of risk for schizophrenia: A double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology, 2002, 27(6), 1056-1070.
[http://dx.doi.org/10.1016/S0893-133X(02)00372-X] [PMID: 12464463]
[14]
Williams, J.M.; Ziedonis, D. Addressing tobacco among individuals with a mental illness or an addiction. Addict. Behav., 2004, 29(6), 1067-1083.
[http://dx.doi.org/10.1016/j.addbeh.2004.03.009] [PMID: 15236808]
[15]
Barr, A.M.; Procyshyn, R.M.; Hui, P.; Johnson, J.L.; Honer, W.G. Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. Schizophr. Res., 2008, 100(1-3), 252-260.
[http://dx.doi.org/10.1016/j.schres.2007.11.027] [PMID: 18178062]
[16]
Goff, D.C.; Henderson, D.C.; Amico, E. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am. J. Psychiatry, 1992, 149(9), 1189-1194.
[http://dx.doi.org/10.1176/ajp.149.9.1189] [PMID: 1503131]
[17]
Cecerska-Heryć, E.; Polikowska, A.; Serwin, N.; Roszak, M.; Grygorcewicz, B.; Heryć, R.; Michalczyk, A.; Dołęgowska, B. Importance of oxidative stress in the pathogenesis, diagnosis, and monitoring of patients with neuropsychiatric disorders, a review. Neurochem. Int., 2022, 153, 105269.
[http://dx.doi.org/10.1016/j.neuint.2021.105269] [PMID: 34971747]
[18]
Murray, A.J.; Rogers, J.C.; Katshu, M.Z.U.H.; Liddle, P.F.; Upthegrove, R. Oxidative stress and the pathophysiology and symptom profile of schizophrenia spectrum disorders. Front. Psychiatry, 2021, 12, 703452.
[http://dx.doi.org/10.3389/fpsyt.2021.703452] [PMID: 34366935]
[19]
Kim, K.B.; Lee, B.M. Oxidative stress to DNA, protein, and antioxidant enzymes (superoxide dismutase and catalase) in rats treated with benzo(a)pyrene. Cancer Lett., 1997, 113(1-2), 205-212.
[http://dx.doi.org/10.1016/S0304-3835(97)04610-7] [PMID: 9065823]
[20]
Yao, J.K.; Keshavan, M.S. Antioxidants, redox signaling, and pathophysiology in schizophrenia: An integrative view. Antioxid. Redox Signal., 2011, 15(7), 2011-2035.
[http://dx.doi.org/10.1089/ars.2010.3603] [PMID: 21126177]
[21]
Wu, J.Q.; Kosten, T.R.; Zhang, X.Y. Free radicals, antioxidant defense systems, and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2013, 46, 200-206.
[http://dx.doi.org/10.1016/j.pnpbp.2013.02.015] [PMID: 23470289]
[22]
MacNEE. W.; Rahman, I. Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 1999, 160(5 Pt 2), S58-S65.
[http://dx.doi.org/10.1164/ajrccm.160.supplement_1.15] [PMID: 10556172]
[23]
Liu, H.; Yu, R.; Gao, Y.; Li, X.; Guan, X.; Thomas, K.; Xiu, M.; Zhang, X. Antioxidant enzymes and weight gain in drug-naive first episode schizophrenia patients treated with risperidone for 12 weeks: A prospective longitudinal study. Curr. Neuropharmacol., 2022, 20(9), 1774-1782.
[PMID: 34544343]
[24]
Li, X.R.; Xiu, M.H.; Guan, X.N.; Wang, Y.C.; Wang, J.; Leung, E.; Zhang, X.Y. Altered antioxidant defenses in drug-naive first episode patients with schizophrenia are associated with poor treatment response to risperidone: 12-week results from a prospective longitudinal study. Neurotherapeutics, 2021, 18(2), 1316-1324.
[http://dx.doi.org/10.1007/s13311-021-01036-3] [PMID: 33791970]
[25]
Morrow, J.D.; Frei, B.; Longmire, A.W.; Gaziano, J.M.; Lynch, S.M.; Shyr, Y.; Strauss, W.E.; Oates, J.A.; Roberts, L.J. II Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med., 1995, 332(18), 1198-1203.
[http://dx.doi.org/10.1056/NEJM199505043321804] [PMID: 7700313]
[26]
Montuschi, P.; Collins, J.; Ciabattoni, G.; Lazzeri, N.; Corradi, M.; Kharitonov, S.A.; Barnes, P.J. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med., 2000, 162(3), 1175-1177.
[http://dx.doi.org/10.1164/ajrccm.162.3.2001063] [PMID: 10988150]
[27]
MacNee, W. Oxidants/Antioxidants and COPD. Chest, 2000, 117(5)(Suppl. 1), 303S-317S.
[http://dx.doi.org/10.1378/chest.117.5_suppl_1.303S-a] [PMID: 10843965]
[28]
Kirkham, P.; Rahman, I. Oxidative stress in asthma and COPD: Antioxidants as a therapeutic strategy. Pharmacol. Ther., 2006, 111(2), 476-494.
[http://dx.doi.org/10.1016/j.pharmthera.2005.10.015] [PMID: 16458359]
[29]
James, R.W.; Leviev, I.; Righetti, A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation, 2000, 101(19), 2252-2257.
[http://dx.doi.org/10.1161/01.CIR.101.19.2252] [PMID: 10811591]
[30]
Ahmadi-Motamayel, F.; Falsafi, P.; Goodarzi, M.T.; Poorolajal, J. Evaluation of salivary catalase, vitamin C, and alpha-amylase in smokers and non-smokers: A retrospective cohort study. J. Oral Pathol. Med., 2017, 46(5), 377-380.
[http://dx.doi.org/10.1111/jop.12495] [PMID: 27800633]
[31]
Northrop-Clewes, C.A.; Thurnham, D.I. Monitoring micronutrients in cigarette smokers. Clin. Chim. Acta, 2007, 377(1-2), 14-38.
[http://dx.doi.org/10.1016/j.cca.2006.08.028] [PMID: 17045981]
[32]
Garg, N.; Singh, R.; Dixit, J.; Jain, A.; Tewari, V. Levels of lipid peroxides and antioxidants in smokers and nonsmokers. J. Periodontal Res., 2006, 41(5), 405-410.
[http://dx.doi.org/10.1111/j.1600-0765.2006.00889.x] [PMID: 16953817]
[33]
Kanehira, T.; Shibata, K.; Kashiwazaki, H.; Inoue, N.; Morita, M. Comparison of antioxidant enzymes in saliva of elderly smokers and non-smokers. Gerodontology, 2006, 23(1), 38-42.
[http://dx.doi.org/10.1111/j.1741-2358.2006.00077.x] [PMID: 16433640]
[34]
Abdolsamadi, H.R.; Goodarzi, M.T.; Mortazavi, H.; Robati, M.; Ahmadi-Motemaye, F. Comparison of salivary antioxidants in healthy smoking and non-smoking men. Chang Gung Med. J., 2011, 34(6), 607-611.
[PMID: 22196063]
[35]
Ahmadi-Motamayel, F.; Falsafi, P.; Abolsamadi, H.; Goodarzi, M.T.; Poorolajal, J. Evaluation of salivary antioxidants and oxidative stress markers in male smokers. Comb. Chem. High Throughput Screen., 2019, 22(7), 496-501.
[http://dx.doi.org/10.2174/1386207322666190806123616] [PMID: 31385764]
[36]
Şenyurt, M.; Aybek, H.; Herken, H.; Kaptanoglu, B.; Korkmaz, A. Evaluation of oxidative status in patients treated with electroconvulsive therapy. Clin. Psychopharmacol. Neurosci., 2017, 15(1), 40-46.
[http://dx.doi.org/10.9758/cpn.2017.15.1.40] [PMID: 28138109]
[37]
Liu, H.; Liu, H.; Jiang, S.; Su, L.; Lu, Y.; Chen, Z.; Li, X.; Li, X.; Wang, X.; Xiu, M.; Zhang, X. Sex-specific association between antioxidant defense system and therapeutic response to risperidone in schizophrenia: A prospective longitudinal study. Curr. Neuropharmacol., 2022, 20(9), 1793-1803.
[http://dx.doi.org/10.2174/1570159X19666211111123918] [PMID: 34766896]
[38]
Virit, O.; Altindag, A.; Yumru, M.; Dalkilic, A.; Savas, H.A.; Selek, S.; Erel, O.; Herken, H. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology, 2009, 60(2), 87-93.
[http://dx.doi.org/10.1159/000239684] [PMID: 19776652]
[39]
Li, X.F.; Zheng, Y.L.; Xiu, M.H.; Chen, D.C.; Kosten, T.R.; Zhang, X.Y. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011, 35(4), 1064-1067.
[http://dx.doi.org/10.1016/j.pnpbp.2011.03.001] [PMID: 21392552]
[40]
Möller, H.J.; Czobor, P. Pharmacological treatment of negative symptoms in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci., 2015, 265(7), 567-578.
[http://dx.doi.org/10.1007/s00406-015-0596-y] [PMID: 25895634]
[41]
Al-chalabi, B.M.; Thanoon, I.A.J.; Ahmed, F.A. Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology, 2009, 59(1), 8-11.
[http://dx.doi.org/10.1159/000202823] [PMID: 19221442]
[42]
Aringhieri, S.; Carli, M.; Kolachalam, S.; Verdesca, V.; Cini, E.; Rossi, M.; McCormick, P.J.; Corsini, G.U.; Maggio, R.; Scarselli, M. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacol. Ther., 2018, 192, 20-41.
[http://dx.doi.org/10.1016/j.pharmthera.2018.06.012] [PMID: 29953902]
[43]
Shiina, A.; Shirayama, Y.; Niitsu, T.; Hashimoto, T.; Yoshida, T.; Hasegawa, T.; Haraguchi, T.; Kanahara, N.; Shiraishi, T.; Fujisaki, M.; Fukami, G.; Nakazato, M.; Iyo, M.; Hashimoto, K. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann. Gen. Psychiatry, 2010, 9(1), 27.
[http://dx.doi.org/10.1186/1744-859X-9-27] [PMID: 20573264]
[44]
Haslemo, T.; Eikeseth, P.H.; Tanum, L.; Molden, E.; Refsum, H. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur. J. Clin. Pharmacol., 2006, 62(12), 1049-1053.
[http://dx.doi.org/10.1007/s00228-006-0209-9] [PMID: 17089108]
[45]
Schoretsanitis, G.; Haen, E.; Stegmann, B.; Hiemke, C.; Gründer, G.; Paulzen, M. Effect of smoking on risperidone pharmacokinetics – A multifactorial approach to better predict the influence on drug metabolism. Schizophr. Res., 2017, 185, 51-57.
[http://dx.doi.org/10.1016/j.schres.2016.12.016] [PMID: 27993531]
[46]
Zhang, X.Y.; Chen, D.C.; Xiu, M.H.; Haile, C.N.; Sun, H.; Lu, L.; Kosten, T.A.; Kosten, T.R. Cigarette smoking and cognitive function in Chinese male schizophrenia: A case-control study. PLoS One, 2012, 7(5), e36563.
[http://dx.doi.org/10.1371/journal.pone.0036563] [PMID: 22570726]
[47]
Koga, M.; Serritella, A.V.; Sawa, A.; Sedlak, T.W. Implications for reactive oxygen species in schizophrenia pathogenesis. Schizophr. Res., 2016, 176(1), 52-71.
[http://dx.doi.org/10.1016/j.schres.2015.06.022] [PMID: 26589391]
[48]
Wang, K.; Xiu, M.; Su, X.; Wu, F.; Zhang, X. Association between changes in total antioxidant levels and clinical symptom improvement in patients with antipsychotic-naïve first-episode schizophrenia after 3 months of risperidone monotherapy. Antioxidants (Basel), 2022, 11(4), 646.
[http://dx.doi.org/10.3390/antiox11040646] [PMID: 35453331]
[49]
Cooper, J.; Mancuso, S.G.; Borland, R.; Slade, T.; Galletly, C.; Castle, D. Tobacco smoking among people living with a psychotic illness: The second Australian survey of psychosis. Aust. N. Z. J. Psychiatry, 2012, 46(9), 851-863.
[http://dx.doi.org/10.1177/0004867412449876] [PMID: 22645396]
[50]
Ischemia-modified albumin: A unique marker of global metabolic risk in schizophrenia and mood disorders. Psychiatry and Clinical Psychopharmacology, 2019, 29(2), 7.
[51]
Ballesteros, A.; Jiang, P.; Summerfelt, A.; Du, X.; Chiappelli, J.; O’Donnell, P.; Kochunov, P.; Hong, L.E. No evidence of exogenous origin for the abnormal glutathione redox state in schizophrenia. Schizophr. Res., 2013, 146(1-3), 184-189.
[http://dx.doi.org/10.1016/j.schres.2013.02.001] [PMID: 23466187]
[52]
Gould, N.S.; Min, E.; Gauthier, S.; Martin, R.J.; Day, B.J. Lung glutathione adaptive responses to cigarette smoke exposure. Respir. Res., 2011, 12(1), 133.
[http://dx.doi.org/10.1186/1465-9921-12-133] [PMID: 21982222]
[53]
Zhang, X.Y.; Tan, Y.L.; Zhou, D.F.; Haile, C.N.; Wu, G.Y.; Cao, L.Y.; Kosten, T.A.R.; Kosten, T. Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology, 2007, 32(9), 2020-2024.
[http://dx.doi.org/10.1038/sj.npp.1301317] [PMID: 17228336]
[54]
Grenhoff, J.; Aston-Jones, G.; Svensson, T.H. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol. Scand., 1986, 128(3), 351-358.
[http://dx.doi.org/10.1111/j.1748-1716.1986.tb07988.x] [PMID: 3788613]
[55]
Hall, R.G.; Duhamel, M.; McClanahan, R.; Miles, G.; Nason, C.; Rosen, S.; Schiller, P.; Tao-Yonenaga, L.; Hall, S.M. Level of functioning, severity of illness, and smoking status among chronic psychiatric patients. J. Nerv. Ment. Dis., 1995, 183(7), 468-471.
[http://dx.doi.org/10.1097/00005053-199507000-00008] [PMID: 7623020]
[56]
Al-Halabí, S.; Fernández-Artamendi, S.; Díaz-Mesa, E.M.; García-Álvarez, L.; Flórez, G.; Martínez-Santamaría, E.; Arrojo, M.; Saiz, P.A.; García-Portilla, M.P.; Bobes, J. Tobacco and cognitive performance in schizophrenia patients: the design of the COGNICO study. Adicciones, 2016, 29(1), 6-12.
[PMID: 27391843]
[57]
Oliveira, R.M.; Siqueira Júnior, A.C.; Santos, J.L.F.; Furegato, A.R.F. Nicotine dependence in the mental disorders, relationship with clinical indicators, and the meaning for the user. Rev. Lat. Am. Enfermagem, 2014, 22(4), 685-692.
[http://dx.doi.org/10.1590/0104-1169.3549.2468] [PMID: 25296154]
[58]
Drew, A.E.; Derbez, A.E.; Werling, L.L. Nicotinic receptor-mediated regulation of dopamine transporter activity in rat prefrontal cortex. Synapse, 2000, 38(1), 10-16.
[http://dx.doi.org/10.1002/1098-2396(200010)38:1<10:AID-SYN2>3.0.CO;2-T] [PMID: 10941136]
[59]
Glassman, A.H. Cigarette smoking: Implications for psychiatric illness. Am. J. Psychiatry, 1993, 150(4), 546-553.
[http://dx.doi.org/10.1176/ajp.150.4.546] [PMID: 8465868]
[60]
Nomikos, G.G.; Schilström, B.; Hildebrand, B.E.; Panagis, G.; Grenhoff, J.; Svensson, T.H. Role of α7 nicotinic receptors in nicotine dependence and implications for psychiatric illness. Behav. Brain Res., 2000, 113(1-2), 97-103.
[http://dx.doi.org/10.1016/S0166-4328(00)00204-7] [PMID: 10942036]
[61]
Patkar, A.A.; Gopalakrishnan, R.; Lundy, A.; Leone, F.T.; Certa, K.M.; Weinstein, S.P. Relationship between tobacco smoking and positive and negative symptoms in schizophrenia. J. Nerv. Ment. Dis., 2002, 190(9), 604-610.
[http://dx.doi.org/10.1097/00005053-200209000-00005] [PMID: 12357094]
[62]
Lohr, J.; Flynn, K. Smoking and schizophrenia. Schizophr. Res., 1992, 8(2), 93-102.
[http://dx.doi.org/10.1016/0920-9964(92)90024-Y] [PMID: 1360812]
[63]
Aguilar, M.C.; Gurpegui, M.; Diaz, F.J.; De Leon, J. Nicotine dependence and symptoms in schizophrenia. Br. J. Psychiatry, 2005, 186(3), 215-221.
[http://dx.doi.org/10.1192/bjp.186.3.215] [PMID: 15738502]
[64]
Dixon, L.; Medoff, D.R.; Wohlheiter, K.; Dixon, L.; Medoff, D.R.; Wohlheiter, K.; DiClemente, C.; Goldberg, R.; Kreyenbuhl, J.; Adams, C.; Lucksted, A.; Davin, C. Correlates of severity of smoking among persons with severe mental illness. Am. J. Addict., 2007, 16(2), 101-110.
[http://dx.doi.org/10.1080/10550490601184415] [PMID: 17453611]
[65]
Barnes, M.; Lawford, B.R.; Burton, S.C.; Heslop, K.R.; Noble, E.P.; Hausdorf, K.; Young, R.M. Smoking and schizophrenia: Is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? Aust. N. Z. J. Psychiatry, 2006, 40(6-7), 575-580.
[http://dx.doi.org/10.1080/j.1440-1614.2006.01841.x] [PMID: 16756583]
[66]
Krishnadas, R.; Jauhar, S.; Telfer, S.; Shivashankar, S.; McCreadie, R.G. Nicotine dependence and illness severity in schizophrenia. Br. J. Psychiatry, 2012, 201(4), 306-312.
[http://dx.doi.org/10.1192/bjp.bp.111.107953] [PMID: 22878134]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy